This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
systemic-lupus-erythematosus
Systemic Lupus Erythematosus
Systemic autoimmune disease from loss of tolerance to nucleic acid antigens; type I IFN signature and complement activation define pathogenesis. Anti-dsDNA and low complement are diagnostic. Hydroxychloroquine is mainstay; belimumab and anifrolumab are approved biologics.
Entry Metadata
| Field | Value |
|---|---|
| ID | systemic-lupus-erythematosus |
| Name | Systemic Lupus Erythematosus |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. · PubMed 22129253
- Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930. · PubMed 22127708
- Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. · PubMed 31851795